Donald A. Richards, MD, PhD

home / authors / donald-a-richards-md-phd

Articles

Dr. Richards on Genetic Testing in Metastatic Pancreatic Cancer

Dr. Richards on Genetic Testing in Metastatic Pancreatic Cancer

Donald A. Richards, MD, PhD
October 21st 2019

Donald A. Richards, MD, PhD, discusses the use of genetic testing in patients with metastatic pancreatic cancer.

Read More

Dr. Richards on Secondary Endpoints of the POLO Trial in Pancreatic Cancer

Dr. Richards on Secondary Endpoints of the POLO Trial in Pancreatic Cancer

Donald A. Richards, MD, PhD
September 27th 2019

Donald A. Richards, MD, PhD, discusses the secondary endpoints of the randomized, double-blind, phase III POLO trial, which evaluated maintenance therapy with olaparib in patients with germline BRCA-mutated, metastatic pancreatic cancer.

Read More

Dr. Richards on Using PARP Inhibitors in Metastatic Pancreatic Cancer

Dr. Richards on Using PARP Inhibitors in Metastatic Pancreatic Cancer

Donald A. Richards, MD, PhD
September 23rd 2019

Donald A. Richards, MD, PhD, discusses the potential benefits of PARP inhibitors in patients with metastatic pancreatic cancer who harbor somatic mutations.

Read More

Dr. Richards on the Phase III POLO Trial in BRCA-Mutated Pancreatic Cancer

Dr. Richards on the Phase III POLO Trial in BRCA-Mutated Pancreatic Cancer

Donald A. Richards, MD, PhD
September 21st 2019

Donald A. Richards, MD, PhD, medical oncologist, Texas Oncology, discusses the design and findings of the phase III POLO trial in patients with pancreatic cancer.

Read More

Dr. Richards on PARP Inhibition in Pancreatic Cancer

Dr. Richards on PARP Inhibition in Pancreatic Cancer

Donald A. Richards, MD, PhD
September 19th 2019

Donald A. Richards, MD, PhD, medical oncologist, Texas Oncology, discusses PARP inhibition in patients with pancreatic cancer.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need